Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Bought by Franklin Resources Inc.

Franklin Resources Inc. lifted its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 4.3% during the third quarter, Holdings Channel reports. The fund owned 21,585 shares of the company’s stock after purchasing an additional 894 shares during the quarter. Franklin Resources Inc.’s holdings in Prestige Consumer Healthcare were worth $1,513,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Victory Capital Management Inc. boosted its stake in shares of Prestige Consumer Healthcare by 9.0% during the 2nd quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock worth $142,827,000 after purchasing an additional 171,357 shares during the last quarter. Arizona State Retirement System boosted its stake in Prestige Consumer Healthcare by 1.9% in the 2nd quarter. Arizona State Retirement System now owns 13,900 shares of the company’s stock worth $957,000 after buying an additional 264 shares during the last quarter. Norden Group LLC grew its holdings in Prestige Consumer Healthcare by 25.9% in the 2nd quarter. Norden Group LLC now owns 12,435 shares of the company’s stock valued at $856,000 after buying an additional 2,559 shares during the period. Quest Partners LLC increased its stake in shares of Prestige Consumer Healthcare by 2,826.7% during the 2nd quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after acquiring an additional 424 shares during the last quarter. Finally, Choreo LLC purchased a new position in shares of Prestige Consumer Healthcare during the 2nd quarter worth about $677,000. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Analysts Set New Price Targets

PBH has been the subject of several research analyst reports. Sidoti lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a research report on Monday, December 9th. Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Wednesday, December 18th. DA Davidson restated a “buy” rating and set a $95.00 price target on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, Prestige Consumer Healthcare currently has an average rating of “Moderate Buy” and a consensus target price of $85.25.

Prestige Consumer Healthcare Stock Down 1.0 %

Shares of NYSE PBH opened at $78.45 on Friday. The stock has a fifty day moving average price of $79.96 and a 200 day moving average price of $73.52. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare Inc. has a 12-month low of $57.95 and a 12-month high of $86.36. The company has a market cap of $3.88 billion, a P/E ratio of 19.09, a P/E/G ratio of 2.32 and a beta of 0.49.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, meeting the consensus estimate of $1.09. The business had revenue of $283.79 million for the quarter, compared to the consensus estimate of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The company’s revenue was down .9% on a year-over-year basis. During the same period last year, the business posted $1.07 EPS. Research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.44 EPS for the current fiscal year.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the sale, the chief executive officer now owns 320,952 shares in the company, valued at $26,510,635.20. This trade represents a 3.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Mary Beth Fritz sold 9,885 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.97, for a total value of $810,273.45. Following the sale, the senior vice president now owns 18,835 shares in the company, valued at $1,543,904.95. This represents a 34.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,810 shares of company stock valued at $3,187,300. Corporate insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.